Corgenix
Medical Corporation CONX announced today it has filed
pre-market notification to the FDA pursuant to Section 510(k) of the
U.S. Federal Food, Drug and Cosmetic Act for its Hyaluronic Acid (HA)
ELISA Test Kit.
The submission follows the completion of a clinical study conducted by
Corgenix and the National Institute of Diabetes and Digestive and Kidney
Diseases (NIDDK) of the National Institutes of Health (NIH) under a
cooperative research and development agreement (CRADA).
The study assessed the Corgenix Hyaluronic Acid (HA) Test Kit as a
marker for liver fibrosis in nonalcoholic steatohepatitis (NASH)
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in